Yusuke Muto

748 total citations
41 papers, 486 citations indexed

About

Yusuke Muto is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Yusuke Muto has authored 41 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Yusuke Muto's work include CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Yusuke Muto is often cited by papers focused on CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Yusuke Muto collaborates with scholars based in Japan, United States and France. Yusuke Muto's co-authors include Takehisa Kaneko, H Yagita, Kiyohiro Ando, Michio Imawari, Nobuhiko Kayagaki, Kazumasa Hiroishi, Takashi Moriyama, Ko Okumura, Taku Fujimura and Yumi Kambayashi and has published in prestigious journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Yusuke Muto

37 papers receiving 481 citations

Peers

Yusuke Muto
Tomoyuki Kawakita Japan
Nikola Baschuk Australia
Misato Amenomori Japan
Martina Hammer Austria
Maurizio Podda Germany
Mary A. Antonysamy United States
Lorenzo Pacenti Italy
Alejandro Sanz‐Bravo Spain
Luciana Nichita Romania
Tomoyuki Kawakita Japan
Yusuke Muto
Citations per year, relative to Yusuke Muto Yusuke Muto (= 1×) peers Tomoyuki Kawakita

Countries citing papers authored by Yusuke Muto

Since Specialization
Citations

This map shows the geographic impact of Yusuke Muto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuke Muto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuke Muto more than expected).

Fields of papers citing papers by Yusuke Muto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusuke Muto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuke Muto. The network helps show where Yusuke Muto may publish in the future.

Co-authorship network of co-authors of Yusuke Muto

This figure shows the co-authorship network connecting the top 25 collaborators of Yusuke Muto. A scholar is included among the top collaborators of Yusuke Muto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuke Muto. Yusuke Muto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamazaki, Emi, Taku Fujimura, Yumi Kambayashi, et al.. (2025). Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration. The Journal of Dermatology. 53(1). 140–144.
2.
Fujisawa, Yasuhiro, Yasuo Yoshioka, Koji Yoshino, et al.. (2025). Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025. The Journal of Dermatology. 52(10). e859–e875. 1 indexed citations
3.
Shida, Naoki, Yusuke Muto, Ryo Kurihara, et al.. (2024). Electrocatalytic Hydrogenation of Pyridines and Other Nitrogen-Containing Aromatic Compounds. Journal of the American Chemical Society. 146(44). 30212–30221. 5 indexed citations
4.
Muto, Yusuke, Yumi Kambayashi, Hiroshi Kato, et al.. (2024). Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. Cancers. 16(15). 2755–2755. 3 indexed citations
5.
Muto, Yusuke, et al.. (2024). Successful treatment of Darier's disease with apremilast and review of reported cases. The Journal of Dermatology. 52(1). 138–141. 1 indexed citations
6.
7.
Muto, Yusuke, Yumi Kambayashi, Hiroshi Kato, et al.. (2022). Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. Acta Dermato Venereologica. 102. adv00756–adv00756. 10 indexed citations
8.
Fujimura, Taku, Yusuke Muto, & Yoshihide Asano. (2022). Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. International Journal of Molecular Sciences. 23(24). 15720–15720. 20 indexed citations
9.
Muto, Yusuke, Eijitsu Ryo, Kenjiro Namikawa, et al.. (2021). RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma. Pathology International. 71(5). 337–347. 5 indexed citations
10.
Muto, Yusuke, Taku Fujimura, Yumi Kambayashi, et al.. (2020). Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy. Dermatologic Therapy. 33(6). e14430–e14430.
11.
Muto, Yusuke, Taku Fujimura, Yumi Kambayashi, et al.. (2020). Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock. Case Reports in Oncology. 13(3). 1141–1144. 3 indexed citations
12.
Takahashi, Akira, Kenjiro Namikawa, Eiji Nakano, et al.. (2020). Efficacy of oral retinoids for keratoacanthoma centrifugum marginatum. Dermatologic Therapy. 33(3). e13291–e13291.
13.
Fujimura, Taku, et al.. (2020). Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid. The Journal of Dermatology. 48(3). 353–359. 8 indexed citations
14.
Tsutsumida, Arata, Satoshi Fukushima, Kenji Yokota, et al.. (2019). Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma. The Journal of Dermatology. 46(11). 947–955. 13 indexed citations
15.
Muto, Yusuke & Shigehisa Kitano. (2019). [Clinical Significance of Ipilimumab and the Combination Therapy as Immune Checkpoint Inhibitor].. PubMed. 46(6). 1011–1015. 1 indexed citations
16.
Namikawa, Kenjiro, Taisuke Mori, Yusuke Muto, et al.. (2018). PD-L1 expression and clinical outcome after nivolumab monotherapy in various subtypes of melanoma: A single-institutional retrospective study. Annals of Oncology. 29. ix105–ix105. 3 indexed citations
17.
Namikawa, Kenjiro, Akira Takahashi, Arata Tsutsumida, et al.. (2017). Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: A single-institutional retrospective study. Annals of Oncology. 28. x114–x114. 1 indexed citations
18.
Thang, Phan Quang, et al.. (2016). Increase in ozone due to the use of biodiesel fuel rather than diesel fuel. Environmental Pollution. 216. 400–407. 3 indexed citations
19.
Muto, Yusuke, et al.. (2015). Adult-Onset Acquired Partial Lipodystrophy Accompanied by Rheumatoid Arthritis. Case Reports in Dermatology. 7(1). 70–74. 1 indexed citations
20.
Ando, Kiyohiro, Kazumasa Hiroishi, Takehisa Kaneko, et al.. (1997). Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. The Journal of Immunology. 158(11). 5283–5291. 222 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoyuki Kawakita Breakdown of academic impact, for papers by Nikola Baschuk Breakdown of academic impact, for papers by Misato Amenomori Breakdown of academic impact, for papers by Martina Hammer Breakdown of academic impact, for papers by Maurizio Podda Breakdown of academic impact, for papers by Mary A. Antonysamy Breakdown of academic impact, for papers by Lorenzo Pacenti Breakdown of academic impact, for papers by Alejandro Sanz‐Bravo Breakdown of academic impact, for papers by Luciana Nichita
Rankless by CCL
2026